Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.52 |
| ▸ | EGFR | P00533 | 4/20 | 0.51 |
| ▸ | SRC | P12931 | 1/20 | 0.51 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | ITK | Q08881 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15756452 | 0.91 | BTK (0.57) | BTKEGFRSRCLCKITK | |
| SCHEMBL15756453 | 0.91 | BTK (0.57) | BTKEGFRSRCLCKITK | |
| SCHEMBL19624641 | 0.90 | BTK (0.52) | BTKEGFRSRCLCKITK | |
| SCHEMBL19544659 | 0.88 | BTK (0.55) | BTKEGFRSRCLCKITK | |
| SCHEMBL19544647 | 0.88 | BTK (0.55) | BTKEGFRSRCLCKITK | |
| SCHEMBL15756479 | 0.88 | BTK (0.49) | BTKEGFRSRCLCKITK | |
| SCHEMBL15756458 | 0.87 | BTK (0.48) | BTKEGFRSRCLCKITK | |
| SCHEMBL20411964 | 0.87 | BTK (0.62) | BTKEGFRSRC | |
| SCHEMBL25060294 | 0.87 | BTK (0.49) | BTKEGFRSRCLCKITK | |
| SCHEMBL19544728 | 0.86 | BTK (0.54) | BTKEGFRSRCLCKITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180207154-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor and/or a JAK-2 Inhibitor | ACERTA PHARMA BV (NL) | 2018-07-26 | — | — | US | disclosed |
| US-20180207154-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor and/or a JAK-2 Inhibitor | ACERTA PHARMA BV (NL) | 2018-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180207154-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor and/or a JAK-2 Inhibitor | BTK, JAK2, JAK1 | BTK 1/4885EGFR 407/4885SRC 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.